No abstract

We showed that there is a definable point where additional information becomes uninformative and may actually lead to less certainty. This evidence supports the concept that clinical decision-making in the assessment of suspected acute coronary syndrome should be focused on obtaining the least amount of information that provides the highest benefit for informing the decisions of admission or discharge.

Summary What is known and objective Drug‐induced immune thrombocytopenia (DITP) is a rare adverse event. It is often diagnosed using clinical risk criteria, but this can create diagnostic uncertainty. Case description A 35‐year‐old man with disseminated Serratia marcescens infection developed severe thrombocytopenia. A drug‐dependent platelet‐reactive antibody test demonstrated cefepime‐dependent platelet‐reactive antibodies which confirmed the diagnosis of DITP. What is new and conclusion We describe the first case of cefepime‐induced DITP confirmed by a drug‐dependent platelet‐reactive antibody test. To our knowledge, this is the first proven example of DITP in a fourth‐generation cephalosporin.